Dr. Reddy's Gets India Approval for Zytorvi in Advanced Esophageal Cancer

• Dr. Reddy's received Indian regulatory approval for Zytorvi as first-line treatment for adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma.
• The treatment combines Zytorvi with cisplatin and paclitaxel, marking its second approved indication in India without requiring PD-L1-based patient selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001575872-26-000715), on October 21, 2026, and is solely responsible for the information contained therein.